Total Payments
$4,164
2024 Payments
$1,023
Companies
49
Transactions
193
Medicare Patients
1,093
Medicare Billing
$289,284
Payment Breakdown by Category
Food & Beverage$4,150 (99.7%)
Education$13.75 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,150 | 192 | 99.7% |
| Education | $13.75 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $522.49 | 12 | $0 (2024) |
| Merck Sharp & Dohme LLC | $474.16 | 26 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $246.58 | 14 | $0 (2024) |
| AbbVie Inc. | $215.53 | 2 | $0 (2021) |
| Celgene Corporation | $170.45 | 3 | $0 (2024) |
| SOBI, INC | $157.50 | 7 | $0 (2023) |
| Tactile Systems Technology Inc | $148.49 | 5 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $134.59 | 8 | $0 (2024) |
| Amgen Inc. | $133.74 | 9 | $0 (2021) |
| Lilly USA, LLC | $131.23 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,023 | 50 | Merck Sharp & Dohme LLC ($239.92) |
| 2023 | $955.00 | 42 | AstraZeneca Pharmaceuticals LP ($214.37) |
| 2022 | $431.92 | 26 | Sobi, Inc ($95.83) |
| 2021 | $757.38 | 37 | AbbVie Inc. ($124.99) |
| 2020 | $375.35 | 18 | Coherus Biosciences Inc. ($62.34) |
| 2019 | $559.31 | 17 | AstraZeneca Pharmaceuticals LP ($135.93) |
| 2018 | $61.67 | 3 | Celgene Corporation ($28.40) |
All Payment Transactions
193 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $29.68 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $31.80 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $13.54 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/13/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $26.54 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $24.10 | General |
| Category: Interventional Oncology | ||||||
| 09/18/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: Oncology | ||||||
| 09/04/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Oncology | ||||||
| 09/04/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $14.48 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 08/28/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $31.93 | General |
| 08/28/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: HEMATOLOGY | ||||||
| 08/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: Oncology | ||||||
| 07/31/2024 | Genentech USA, Inc. | Kadcyla (Biological), Perjeta, Phesgo | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: BioOncology | ||||||
| 07/31/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $14.94 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 07/24/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 340 | 3,122 | $319,525 | $93,675 |
| 2022 | 7 | 243 | 2,684 | $229,530 | $65,387 |
| 2021 | 7 | 221 | 2,537 | $168,638 | $59,620 |
| 2020 | 10 | 289 | 2,324 | $181,478 | $70,603 |
Total Patients
1,093
Total Services
10,667
Medicare Billing
$289,284
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 27 | 2,400 | $134,040 | $44,093 | 32.9% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 23 | 165 | $86,625 | $22,416 | 25.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 76 | 98 | $31,070 | $9,574 | 30.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 64 | 77 | $34,138 | $9,370 | 27.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $12,535 | $3,794 | 30.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 35 | 43 | $7,525 | $1,914 | 25.4% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 33 | 188 | $5,272 | $1,270 | 24.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 59 | 128 | $8,320 | $1,243 | 14.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 26 | 2,100 | $111,300 | $35,845 | 32.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 21 | 132 | $69,300 | $18,162 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 49 | 60 | $19,080 | $5,268 | 27.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 40 | 48 | $8,400 | $2,358 | 28.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $5,995 | $1,333 | 22.2% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2022 | 40 | 218 | $7,980 | $1,267 | 15.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 56 | 115 | $7,475 | $1,154 | 15.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 25 | 2,040 | $75,720 | $33,647 | 44.4% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 17 | 93 | $48,825 | $13,020 | 26.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 50 | 71 | $19,280 | $6,304 | 32.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 32 | 43 | $7,490 | $2,416 | 32.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $4,748 | $1,719 | 36.2% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2021 | 31 | 181 | $6,335 | $1,526 | 24.1% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 53 | 96 | $6,240 | $987.01 | 15.8% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2020 | 22 | 158 | $79,800 | $26,848 | 33.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 24 | 1,680 | $58,800 | $26,235 | 44.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 27 | 27 | $7,047 | $4,327 | 61.4% |
About Dr. Reid Culton, D.O
Dr. Reid Culton, D.O is a Family Medicine healthcare provider based in Klamath Falls, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215023791.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Reid Culton, D.O has received a total of $4,164 in payments from pharmaceutical and medical device companies, with $1,023 received in 2024. These payments were reported across 193 transactions from 49 companies. The most common payment nature is "Food and Beverage" ($4,150).
As a Medicare-enrolled provider, Culton has provided services to 1,093 Medicare beneficiaries, totaling 10,667 services with total Medicare billing of $289,284. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Other Specialties Family Medicine, Family Medicine
- Location Klamath Falls, OR
- Active Since 10/04/2006
- Last Updated 06/09/2017
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1215023791
Products in Payments
- KEYTRUDA (Biological) $474.16
- FARXIGA (Drug) $208.17
- UBRELVY (Drug) $183.13
- TEZSPIRE (Biological) $125.00
- VERZENIO (Drug) $119.28
- JAKAFI (Drug) $100.56
- KISQALI (Drug) $97.41
- IMBRUVICA (Drug) $95.90
- DOPTELET (Drug) $95.83
- Flexitouch Plus (Device) $94.50
- NINLARO (Drug) $93.81
- Mavyret (Drug) $90.54
- Doptelet (Drug) $90.43
- BRUKINSA (Drug) $79.41
- FOTIVDA (Drug) $77.19
- Xtandi (Drug) $76.67
- GILOTRIF (Drug) $72.81
- ORGOVYX (Drug) $69.81
- XTANDI (Drug) $65.94
- PLUVICTO (Drug) $63.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Klamath Falls
Nellie Wirsing, Md, MD
Family Medicine — Payments: $4,145
Family Medicine $4,145
Dr. Alden Glidden, M.d, M.D
Family Medicine — Payments: $2,260
Family Medicine $2,260
Dr. Kathie Lang, M.d, M.D
Family Medicine — Payments: $1,247
Family Medicine $1,247
Mrs. Shelley Janssen, M.d, M.D
Family Medicine — Payments: $676.43
Family Medicine $676.43
Dr. Cathleen O'farrell, M.d, M.D
Family Medicine — Payments: $424.61
Family Medicine $424.61
Jon Mckellar, Md, MD
Family Medicine — Payments: $385.07
Family Medicine $385.07